More than 1,200 clinical trials across the world faced some kind of disruption due to the Covid-19 outbreak.
The most common disruptions were slow enrolment, suspension of registration and delayed initiation of trials.
Go deeper with GlobalData
According to GlobalData, the number of disrupted trials peaked in June 2020, following which the figure declined marginally.
Clinical Trials that Have Been Disrupted
However, clinical trials affected by slow enrolment were steadily increasing, as of 27 July 2020.
Overall, around 50% of the clinical trials were impacted due to enrolment suspension amid the pandemic. Slow enrolment and delayed initiation accounted for 33% and 17% of the disruptions, respectively.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe information is based on GlobalData’s Pharmaceutical Intelligence Centre and Clinical Trials Database.
